AlloDirect's AI-Enabled Tissue Marketplace Boosts Efficiency, Savings

🎙️ New Podcast on Podiatry Today: Biologics in Foot and Ankle Pathology hosted by our own Jennifer Spector, DPM, FACFAS Biologics continue to reshape how we think about healing, regeneration, and surgical outcomes in foot and ankle care. In this latest Podiatry Today Podcast, our guest takes a deeper dive into how biologic therapies are being used across a range of pathologies—from soft tissue injuries to complex surgical cases. The conversation explores: 🔬 The science behind biologics and how they support tissue healing 🦶 Clinical scenarios where biologics may enhance outcomes ⚖️ Practical considerations when deciding if and when to incorporate them into treatment plans 🎧 Listen to the full discussion here: https://lnkd.in/eutPz85H #Podiatry #FootAndAnkle #Biologics #RegenerativeMedicine #PodiatryToday

Are we prepared to address the "Logistic Crisis" in modern clinical ophthalmology? The relentless burden of frequent intraocular injections for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) remains a profound challenge for both patients and medical facilities. However, a decisive paradigm shift is on the horizon. Chugai Pharmaceutical has filed for domestic approval of the Port Delivery System (PDS), an innovative intraocular implant designed to redefine anti-VEGF therapy. This marks a fundamental transition from intermittent "points" of treatment to continuous "lines" of drug release. In my latest Substack article, I provide a comprehensive analysis of the PDS (internationally known as Susvimo) and its potential to serve not merely as a device upgrade, but as a future platform for sustained-release therapeutics. Key insights discussed in the article: The transition from disposable injections to a refillable drug reservoir. The anatomical advantages of continuous drug release (the "Drying" effect). The delicate balance between genuine enhancement of Quality of Life (QOL) and surgical risks. Can we transcend the treatment of the "local eye" to redefine the broader quality of healthcare? I invite all clinicians, researchers, and industry professionals navigating these clinical challenges to read my full consideration and join the discussion. Read the full article on my Substack here: https://lnkd.in/gPXjwTif #Ophthalmology #nAMD #DME #DrugDeliverySystem #PDS #ClinicalResearch #MedicalInnovation #Retina

HLB Life Science secures tissue bank license, expanding into the ‘human tissue transplant’ business HLB Life Science has acquired a ‘tissue bank’ license, marking the start of its full-scale expansion into the human tissue transplantation business. With this approval, the company has established the necessary foundation to handle human-derived tissues such as bone, cartilage, fascia, and skin, enabling it to actively advance related business operations. According to HLB Life Science on March 24, this license acquisition represents a follow-up milestone to the exclusive domestic distribution agreement for human tissue grafts signed last month with Orthotech, a medical device specialist. Leveraging this tissue bank license, the company plans to expand its hospital sales network nationwide and further strengthen its market penetration. ‘PREDERM Inject re:fill,’ which HLB Life Science plans to distribute, is a human-derived acellular allogeneic dermal injectable. As a human tissue-based product utilizing acellular dermis as a raw material, it is indicated for the treatment of damaged tissues, including ligaments, tendons, and muscles, as well as for use as surgical supplementation. Its ability to be stored at room temperature is expected to offer high convenience in clinical settings. https://lnkd.in/ezRMiPnK

Proud to share that AlloDirect, Inc. has joined the Free Market Medical Association (FMMA). Their commitment to transparent, market-driven healthcare perfectly aligns with our mission to bring clear, predictable biologic procurement and direct connections to accredited tissue banks and ASCs. By standing alongside providers, employers, and solution partners who believe in up-front prices, value-based care, and willing-buyer/willing-seller relationships, we’re helping build a more sustainable and ethical supply chain for tissue distribution. Thank you to the FMMA community for welcoming us - excited to contribute to the movement toward transparency in healthcare purchasing. Ambulatory Surgery Center Association (ASCA) Illinois Bone & Joint Institute Illinois Ambulatory Surgery Center Association Keith Smith MTF Biologics AlloSource® Solvita DCI Donor Services, Inc. LifeLink Foundation Osiris Therapeutics OrthoCarolina OrthoVirginia OrthoAlliance Indiana Orthopedic Institute OrthoIndy AMSURG Tenet Healthcare Northwestern Medicine UPMC Supply Chain Management United Surgical Partners International, Inc SCA Health HCA HealthONE Sutter Health Surgery Ventures, powered by HCA Healthcare Orthopedic ONE OrthoSouth - Orthopedic Care Ascension Ventures Abundant Venture Partners Health Engine Fort Wayne Orthopaedics Midwest Orthopaedics at Rush JIS Orthopedics OCA Ventures Frist Cressey Ventures Henry Ford Innovations Healthcare Shares Oracle Health Samsung Healthcare

📣 Oculis Reports Q4 2025 Results and Strategic Milestones 💊 OCS-01 🏢 Oculis Holding AG 🫀 diabetic macular edema Oculis Holding AG reported significant advancements in its clinical portfolio for 2025, particularly with OCS-01 and Privosegtor, positioning the company for strong growth in ophthalmology and neuro-ophthalmology. The forthcoming topline results from the DIAMOND Phase 3 trials for OCS-01, aimed at diabetic macular edema (DME), are due in Q2 2026, with a potential NDA submission by Q4 2026. This drug stands to serve the vast unmet needs in the current DME market, which totals about $3 billion, by targeting the 1.3 million patients who are currently underserved. Additionally, the FDA granted Breakthrough Therapy designation to Privosegtor for optic neuritis, further summarizing a market opportunity exceeding $7 billion in the U.S. alone. Financially, Oculis ended 2025 with an impressive cash balance of approximately $268.7 million, significantly up from $109 million in the prior year, primarily due to successful equity financings totaling $210 million. However, the company reported a net loss of $119.1 million for the year, higher than the previous year's loss, driven by increased research and development expenses as they advance their late-stage portfolio and expand into new therapeutic areas. Despite operating losses, the healthy cash reserve positions Oculis well for future clinical advancements and potential expansion in the lucrative ophthalmic market, estimated at $30 billion, highlighting the strategic value of their ongoing clinical trials and innovative approaches in treating complex ophthalmic conditions. Read full article: https://lnkd.in/gDD5eyGM #ophthalmology #OCS01 #OculisHoldingAG

🚨 Arch Biopartners announced that St. Michael’s Hospital (Unity Health Toronto) has commenced patient dosing in the Company’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The update also includes operational progress across Canadian sites, next-step planning for additional sites, and an update on the investigator-led Phase II PONTiAK trial evaluating cilastatin in AKI associated with nephrotoxic pharmaceuticals. 📖 Read the full release: https://lnkd.in/ehQ3w3pK #ArchBiopartners #LSALTpeptide #AKI #CSAKI #Cilastatin #DPEP1 #ClinicalTrials #ArchNews #KidneyCare

At Telara Pharma, we closely follow the clinical validation of #cilastatin in acute kidney injury (AKI). We are proud to collaborate with Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) as our partner for AKI applications, as the Phase II PONTiAK trial continues to demonstrate a strong safety profile and meaningful clinical progress. #cilastatin #acute kidney injury #AKI #clinical trial #PONTiAK

GS MedTech Industry Update - Leadership Appointments - Week 10, 2026 HEARTio appointed Dr. John Jefferies to its Clinical Advisory Board. The cardiology and AI-in-healthcare expert will support the clinical development of HEARTio’s AI-driven cardiac diagnostics platform. Cerenion Oy named Kiki Di Napoli as Vice President of Sales to accelerate commercial adoption of its AI-powered C-Trend® EEG technology. Nuventus Inc appointed Melker Nilsson as Strategic Advisor and Independent Director and Kishore Pranjivan as Strategic Advisor as the dental implant company prepares for global expansion, including Canada. Shoulder Innovations added MedTech veteran Drew Hykes to its Board of Directors to support continued growth of its shoulder arthroplasty platform. mOm Incubators welcomed Dr. Joshua Boger, founder and former CEO of Vertex Pharmaceuticals, to its Board to guide the global scaling of its maternal and neonatal care technologies. ContextVision AB appointed Marco Marien Voormolen as Chief Technology Officer as the company advances its quantitative imaging and AI solutions. Renata Medical named Andrew Cormack as Chief Commercial Officer to lead commercial expansion of its congenital heart technologies. Salvia BioElectronics appointed Kevin Claes as Director of Therapy Development to advance its neuromodulation therapies for chronic migraine. B. Braun Group Türkiye appointed Pascal Paul as General Manager, marking a leadership transition for its Turkish operations. Cellbox Solutions appointed Dr. Bernd Muehlenweg as Chief Business Officer and Chief Financial Officer following the first tranche of its Series A financing to support international expansion of its warm-chain logistics platform. VDyne appointed Mike Buck as Chairman and CEO to lead the next phase of development for its transcatheter tricuspid valve replacement (TTVR) program. Coloplast appointed Gavin Wood as President and CEO, effective May 1, 2026. He joins from Johnson & Johnson MedTech EMEA and will take over from interim CEO Lars Rasmussen. Congrats to all.

Do you know how adipose tissue banking works? Adipose tissue banking involves a minimally invasive mini-liposuction under local anesthesia (approximately 30 to 60 minutes, outpatient), tissue processing and characterization, cryoprotectant addition, controlled-rate freezing, and long-term storage in liquid nitrogen vapor at approximately -196 degrees Celsius. Published research shows that cryopreserved adipose tissue retains cell viability and stem cell isolation potential after years of storage. The process is regulated under 21 CFR Part 1271 and subject to current good tissue practice (CGTP) requirements. Banking preserves tissue for potential future use in FDA-regulated clinical pathways; it does not guarantee access to any treatment. → https://lnkd.in/dbYYYy2X ----- Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.

【生生不息🧬｜Biologics in Surgeries Ep4】 Co-hosted by Docquity and APlus Biotechnology, this series focuses on the clinical integration and innovative applications of biologic therapies in surgical practice. #Episode 4 This session highlights the clinical application of regenerative medicine in otologic surgery, with a focus on the treatment of chronic otitis media and chronic tympanic membrane perforation. The discussion will explore how biologic therapies can support tissue repair and functional recovery when conventional surgical techniques reach their limitations. This webinar combines clinical experience in endoscopic ear surgery with regenerative strategies using autologous platelet-derived biologics (e.g., PRP). Through real clinical cases and decision-making insights, ENT specialists will gain a clearer understanding of the role, indications, and clinical value of regenerative medicine in ear surgery, bringing a more comprehensive and forward-looking perspective to clinical practice. 🗓 Date & Time:：March 06, 2026 (Fri) | 19:00–20:00 🔻 Live on Docquity https://lnkd.in/gsWT5GHR --------------- #How to Join the Webinar for Free 1️⃣ Click the link or scan the QR code to log in / register for free on Docquity 2️⃣ Click “Register” to receive a reminder before the live session 3️⃣ Follow the “A Plus Life” channel to stay updated on the Endless Regeneration webinar series 🔻 Register now for free! In this session you will learn: ✅ Latest clinical evidence of PRP in otologic regenerative medicine ✅ Clinical applications of biologics in tympanic membrane repair ✅ Regenerative strategies in endoscopic surgery for chronic otitis media ✅ Injection techniques, safety considerations, and clinical case outcomes